Germany’s privately-held immatics biotechnologies GmbH and Swiss drug major Roche (ROG: SIX) have entered into a strategic R&D collaboration covering multiple cancer vaccines and immunotherapeutics that could earn the biotech firm as much as $1 billion.
Under the terms of the accord, immatics will receive an upfront $17 million and committed research funding plus potential milestone payments that could reach values in excess of $1 billion and royalties across three cancer indications, based on sales of the cancer vaccines and immunotherapies resulting from this agreement.
Most advanced candidate, IMA942, ready for Ph I
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze